Monoclonal antibodies and their fragments in cancer treatment;L'utilisation des anticorps ou de leurs fragments pour le traitement des tumeurs

Bulletin du Cancer

Volumn 85, Issue 11, 1998, Pages 951-959

  Douillard, Jean Yves ^a   Chatal, Jean François ^a  

^a CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

Immunoconjugate; Passive immunotherapy; Radioimmunotherapy

Indexed keywords

ANTIBODY CONJUGATE;

ACUTE LEUKEMIA; BONE MARROW TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; HUMAN; NONHODGKIN LYMPHOMA; RADIOIMMUNOTHERAPY; REVIEW; TREATMENT OUTCOME; TUMOR LOCALIZATION;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTHERAPY; IMMUNOTOXINS; LEUKEMIA; LYMPHOMA; NEOPLASMS; RADIOIMMUNOTHERAPY;

EID: 0032430088     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. KölherG, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975 ; 256 : 495-7.
2. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Führer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Gent 1979 ; 5 : 957-72.
3. DouillardJY, Le Mevel B, Gurtet C, Vignoud J, Chatal JF, Koprowski H. Immunotherapy of gastro-intestinal cancer with monoclonal antibodies, filed Oncol Tumor Phannacother 1986 ; 3 : 141-6.
4. DouillardJY, Lehur PA, Vignoud J, Blottière H, Maurel C, ThedrezP, Kremer M, et al. Monoclonal antibody specific immunotherapy of gastrointestinal tumors. Hybridoma 1986 ; 5 (SI) : 139-49.
5. FrodinJE, Harmenberg U, Biberfeld P, Christensson B, LefvertA, Rieger A, et al. Clinical effect of monoclonal antibodies in patients with metastatic colorcctal carcinomas. Hybridoma 1988 ; 7 : 309-21.
6. Mellstedt H, FrodinJE, Masucci G, Ragnhammar P, FagerbergJ, Hjelm AL, et al. The therapeutic use of monoclonal antibodies in colorectal carcinoma. Semin Oncol 199 \; 18 : 462-77.
7. Blottière H, Douillard JY, Koprowski H, Steplewski Z. Tumoral and cellular responses of colorectal cancer patients treated with monoclonal antibodies and Interferon y. Cancer Immiinol Immunother 1990 ; 32 : 2937.
8. Riethmuller G, Schneider-Gadicke E, SchlimokG, Schmiege! W, Raab R, Hofïken K, et al. and the German Cancer Aid 17-1A Study Group. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes C colorectal carcinoma. Lancet 1994 ; 343 : 1177-83.
9. Roy DC, Ovellet S, Le Mouillier C, Ariniello PD, Perreault C, Lambert JM. Elimination of neuroblastoma and small cell lung cancer cells with an anti-neural cell adhesion molecule immunotoxin. J Nad Cancer fl 996; 88: 1136-45.
10. Press O, EaryJ, Martin P, Appelbaum F, Nelp W, Matthews D, et al. A phase II trial of iodine-131-labeled anti-CD20 (Bl) antibody therapy with bone marrow transplantation for relapsed non-Hodgkin's lymphomas. ProcAm Soc Clin Oncol 1995 ; 14 : 388.
11. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, MilikAW, et al. Iodine-131-anti-Bl radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996 ; 14 : 1974-81.
12. Czuczman MS, Straus DJ, Divgi CR, Graham M, Garin-Chesa P, Finn R, et al. Phase I dose-escalation trial of iodine-131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. J Clin Oncol 1993; 11 : 2021-9.
13. Juweid M, Sharkey RM, Markowitz A, Behr T, Swayne LC, Dünn R, et al. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Canr(TA 1995; 55: 5899s-907s.
14. De Nardo G, De Nardo S, Lewis J, Salako Q, Levy N, Goldstein D, et al. Maximum tolerated dose of 1-131 Lym-1 in non-Hodgkin's lymphoma : responses and toxicities. ProcAm Soc Clin Oncol 1994 ; 13 : 368.
15. Matthews DC, Appelbaum F, EaryJF, Fisher DR, Durack LD, Bush SA, et al. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 1311-labeled anti-CD45 antibody combined with cyclophosphamide and total body irradiation. Blood 1995 ; 85 : 1122-31:
16. Matthews DC, Appelbaum FR, EaryJF, Mitchell D, Press OW, Bernstein ID. l3'I-anti-CD45 antibody plus Busulfan/Cyclosphophamide in matched related transplants for AML in first remission. Blood 1996 ; 88: 142a (abstr).
17. Jurcic JG, Caron PC, Nikula TK, Papadopoulos EB, Finn RD, Cansow OA, et al. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res 1995 ; 55 : 5908s-10s.
18. Deb N, Goris M, Trisler K, Fowler S, Saal J, Ning S, et al. Treatment of hormone-refractory prostate cancer with Y-CYT-356 monoclonal antibody. Clin Cancer Res 1996 ; 2 : 1289-97.
19. Divgi CR, Scott LD, Dantis L, Capitelli P, Siler K, Hilton S, et al. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma. J Nucl Meet 1995 ; 36 : 586-92.
20. Lane DM, Eagle KF, Begent RHJ, Hope-Stone LD, Green AJ, CaseyJL, et al. Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labellcd antibody to carcinoembryonic antigen : phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies. BrJ Cancer 1994 ; 70 : 521-5.
21. Meredith RF, BueschenAJ, Khazaeli MB, Plott WE, Grizzle WE, Wheeler RH, et al. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49./ Nud Med 1994 ; 35 : 1017-22.
22. Rosenblum MG, Macey D, PodolofTD, Kasi L, BayouthJ, Cunningham J, et al. A phase I pharmacokinetic, toxicity and dosimetry study of 1311 labeled IMMU-4 F(ab')2 in patients with advanced colorectal carcinoma. Antibod Immunoconj Radiopharm 1993 ; 6 : 239-55.
23. Welt S, Scott AM, Divgi CR, Kemeny NE, Finn RD, Daghighian F, et al. Phase I/II study of iodine 125-labeled monoclonal antibody A33 in 1 patients with advanced colon cancer. J Clin Oncol 1996 ; 14 : 1787-97.
24. Yu B, CarrasquilloJ, Milenic D, Chung Y, Perentesis P, Feuerestein I, et al. Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies : influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics. J Clin Oncol 1996 ; 14 : 1798-809.
25. Juweid ME, Sharkey RM, Behr T, Swayne LC, Dünn R, Siegel J, et al. Radiommunotherapy of patients with small-volume tumors using iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab')2. J Nucl Med 1996; 37: 1504-10.
26. Juweid ME, Sharkey RM, Behr T, Swayne LC, Herskovic T, PereiraM, Rubin AD, Hanley D, Dünn R, Siegel J, Goldenberg DM. Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies. J Nud Med 1996 ; 37 : 905-11.
27. BardiesM, Bandet S, Faivre-Chauvet A, PeltierP, DouillardJY, Mahé M, et al. Bispecific antibody and iodine-131-labeled bivalent hapten dosimetty in patients with medullary thyroid or small-cell lung cancer. J Nucl Med 19% ; 37 : 1853-9.
28. Schlumberger M, Arcangioli O, Piekarski JD, Tubiana M, Parmen-tier C. Detection and treatment of lung métastases of differentiated thyroid carcinoma in patients with normal chest X-rays. ] Nud Mtd 1988; 29: 1790-4.
29. Goodwin TA. Tumor pretargeting: almonst the bottom line. J Nud AW 1995; 36: 876-9